FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

25 letters match. Newest first.

  1. kdc/one Chatsworth, Inc.

    FDA warned kdc/one Chatsworth of CGMP violations in OTC drugs, including missing carcinogen testing and storage temperature failures.

    High risk
  2. Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd.

    Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.

    High risk
  3. GC America, Inc.

    FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.

    High risk
  4. IDO Pharm Co., Ltd.

    IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.

    High risk
  5. Medical Products Laboratories, Inc.

    Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.

    High risk
  6. Creative Essences, Inc.

    FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.

    High risk
  7. Dixon Investments Inc. dba ARI

    FDA cites Dixon Investments (ARI) for manufacturing-rule and unapproved/misbranded OTC aerosol drug violations.

    High risk
  8. Anhui Hanbon Daily Chemical Co., Ltd.

    FDA warns Anhui Hanbon Daily Chemical over CGMP failures in OTC drugs, including use of an incorrect excipient and untested ingredients.

    High risk
  9. Macsen Drugs

    FDA cites Macsen Drugs for releasing fire-exposed APIs and inadequate stability data at India plant.

    High risk
  10. Exela Pharma Sciences, LLC

    Exela Pharma Sciences failed CGMP (current good manufacturing practice) for sterile injectable drugs, including invalidated sterility-media tests and inaccurate microbiology records.

    High risk
  11. BioAsia Worldwide Sdn Bhd

    FDA warned BioAsia Worldwide over current good manufacturing practice violations for OTC drugs.

    High risk
  12. Sombra Cosmetics, Inc.

    FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.

    High risk
  13. Originitalia SRL

    FDA warns Originitalia SRL over manufacturing quality failures in OTC drugs, including untested active ingredient and missing release testing.

    High risk
  14. Azurity Pharmaceuticals, Inc.

    FDA warned Azurity Pharmaceuticals over unapproved FIRST drug kits and manufacturing quality failures at its Wilmington, MA plant.

    High risk
  15. LS Promotions Inc.

    LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.

    High risk
  16. Neobiosis, LLC

    FDA warns Neobiosis over unapproved amniotic fluid and umbilical cord products and serious manufacturing quality failures.

    High risk
  17. Global Cosmetics Company Limited

    FDA warns Global Cosmetics over manufacturing quality failures in OTC hand sanitizer, including no methanol testing of ethanol.

    High risk
  18. Atlantic Management Resources LTD dba. Claire Ellen Products

    Atlantic Management Resources (Claire Ellen Products) had CGMP violations and distributed unlisted Neuroquell Plus Cream.

    Medium
  19. Delta Kozmetik Sanayi Ve Ticaret-Selim Yesil

    FDA warned Delta Kozmetik that its OTC drug products were adulterated due to CGMP violations.

    High risk
  20. MD Pharmaceutical Supply, LLC

    FDA warns MD Pharmaceutical Supply over API repackaging failures, including redistributing a returned lot and uncontrolled cross-contamination risks.

    High risk
  21. Kari Gran Inc.

    Kari Gran Inc. released OTC SPF sunscreen drugs without adequate batch testing or stability data.

    High risk
  22. Cosmo Bio Co., Ltd.

    FDA cited South Korea's Cosmo Bio for CGMP failures and for selling an unapproved, misbranded acne drug serum in the U.S.

    High risk
  23. Matthew 7:25 Inc dba Thrive Pharmacy

    FDA says Thrive Pharmacy compounded drugs without valid prescriptions and released subpotent buprenorphine troches, making them adulterated and misbranded.

    High risk
  24. CellEra LLC

    CellEra LLC's sterile silver wound dressings have repeated quality-system violations and uncleared labeling claims, FDA says.

    High risk
  25. Maitland Labs of Central Florida

    FDA warns Maitland Labs of Central Florida over sterile compounded drugs with manufacturing quality failures, mislabeling, and unapproved new drug violations.

    High risk